Published in Medical Letter on the CDC and FDA, November 6th, 2005
There were no material changes to the prescribing information insert for Zyflo as a result of the FDA review. Zyflo is expected to be available to patients before the end of October 2005.
According to the company, Zyflo is the only FDA-approved asthma treatment that inhibits the production of 5-lipoxygenase (5-LO), the main enzyme...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA